Use of major GLP-1 medicines for weight management rose sharply in the United States between 2021 and 2025, but a new study reports that access did not expand evenly among people who were eligible for treatment.

Researchers led by Boston University School of Public Health examined prescription fills for semaglutide and tirzepatide among adults with overweight or obesity who did not have type 2 diabetes. The study, published in Health Affairs Scholar, found that the share of eligible patients filling a prescription within six months of becoming eligible increased from 1.9% in 2021 to 16.6% in 2025.

At the same time, the researchers found lower prescription rates among men, Black or Hispanic patients, people aged 18 to 34 or 55 to 64, people in a lower body-mass-index category, and patients whose providers were located in neighborhoods with lower socioeconomic status. The disparities widened over time, particularly in 2024 and 2025.

A rapid rise with uneven reach

GLP-1 receptor agonists have shifted rapidly from relatively specialized medicines for type 2 diabetes into widely discussed treatments for weight management, cardiovascular health and other emerging uses. Semaglutide is sold as Ozempic and Wegovy, while tirzepatide is sold as Mounjaro and Zepbound.

These medicines mimic a natural hormone involved in regulating insulin, blood sugar, appetite and digestion. The source article notes that they can help people achieve substantial weight loss, especially people who have struggled to lose weight through diet and exercise alone.

The new findings add a distributional question to the debate over their growth: who is actually receiving the medicines as their clinical use expands? A national increase in prescriptions does not necessarily mean that every eligible group is seeing comparable access.

In this study, the overall trajectory was unmistakable. The proportion of eligible people filling a prescription within six months grew nearly ninefold from 2021 to 2025. But the subgroup results suggest that the growth was concentrated unevenly across the population.

Where the disparities appeared

The researchers identified several groups with lower rates of prescriptions. Men received prescriptions at lower rates than other eligible patients. Black and Hispanic patients also had lower prescription rates, as did younger adults aged 18 to 34 and adults aged 55 to 64.

Despite soaring demand for GLP-1s, many eligible patients are unable to access these drugs for weight loss
A–F: Trends of semaglutide and tirzepatide prescription within 6 months of medication eligibility. Abbreviations: BMI, body mass index; GLP-1, glucagon-like peptide-1; RA, receptor agonist; SES, socioeconomic status. Credit: Health Affairs Scholar (2026). DOI: 10.1093/haschl/qxag255

Patients in a lower BMI category were less likely to receive the medicines. The study also found lower prescribing when a patient’s health-care provider was located in a neighborhood with lower socioeconomic status, using education levels in the provider’s ZIP code as its measure of socioeconomic status.

These patterns matter because eligibility alone does not guarantee that a person can begin treatment. The study’s focus on prescriptions filled within six months of medication eligibility captures a point at which clinical qualification needs to become an actual filled prescription. Any barrier before or during that step can affect whether a patient obtains the treatment.

The gap grew after weight-management approvals

The differences became particularly pronounced in 2024 and 2025. Those years followed the Food and Drug Administration’s approvals of semaglutide for chronic weight management in 2021 and tirzepatide for chronic weight management in 2023.

That timing suggests a difficult transition: medicines can gain formal approval and rapidly enter public awareness while access remains unequal. The expansion of a treatment category can therefore increase the visibility of underlying differences in health-care access rather than automatically resolving them.

The article identifies affordability and accessibility as persistent concerns. As demand climbs, those challenges may shape which eligible people are able to receive drugs that have become central to discussions of obesity treatment and metabolic health.

Why the findings are significant

GLP-1 medicines have generated exceptional demand because of their potential effects on weight and related health risks. Their rising use has also created intense public attention around availability, cost and coverage. The Boston University-led study places evidence behind a concern that access may be stratified by demographic and socioeconomic factors.

For health systems and policymakers, the key issue is not merely how many prescriptions are being written. It is whether the pathways to treatment work similarly for people who meet the same broad eligibility criteria. The study indicates that they do not.

The results do not establish a single reason for every difference in prescribing. They do, however, document a widening pattern across several groups. That makes access itself an important part of evaluating the real-world impact of the therapies.

Questions raised by the study

  • Why are eligible men, Black and Hispanic patients, and certain age groups less likely to fill prescriptions?
  • How do affordability and other access barriers affect treatment uptake?
  • What role does the socioeconomic context of a provider’s location play in access?
  • Will the disparities narrow as use of semaglutide and tirzepatide continues to grow?

The study’s central finding is a dual one. GLP-1 weight-management treatment expanded substantially in a short period, yet that expansion was accompanied by larger gaps between groups. As these medicines become more established in care, closing those gaps may be as consequential as sustaining the growth in overall availability.

This article is based on reporting by Medical Xpress. Read the original article.

Originally published on medicalxpress.com